These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27797961)

  • 1. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.
    Wang D; Freed DC; He X; Li F; Tang A; Cox KS; Dubey SA; Cole S; Medi MB; Liu Y; Xu J; Zhang ZQ; Finnefrock AC; Song L; Espeseth AS; Shiver JW; Casimiro DR; Fu TM
    Sci Transl Med; 2016 Oct; 8(362):362ra145. PubMed ID: 27797961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.
    Fu TM; An Z; Wang D
    Vaccine; 2014 May; 32(22):2525-33. PubMed ID: 24681264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.
    Fu TM; Wang D; Freed DC; Tang A; Li F; He X; Cole S; Dubey S; Finnefrock AC; ter Meulen J; Shiver JW; Casimiro DR
    Vaccine; 2012 Dec; 30(52):7469-74. PubMed ID: 23107592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.
    Plachter B
    Med Microbiol Immunol; 2016 Dec; 205(6):537-547. PubMed ID: 27519596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
    Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
    J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
    Schneider-Ohrum K; Cayatte C; Liu Y; Wang Z; Irrinki A; Cataniag F; Nguyen N; Lambert S; Liu H; Aslam S; Duke G; McCarthy MP; McCormick L
    J Virol; 2016 Nov; 90(22):10133-10144. PubMed ID: 27581989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
    Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
    Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.
    Loughney JW; Rustandi RR; Wang D; Troutman MC; Dick LW; Li G; Liu Z; Li F; Freed DC; Price CE; Hoang VM; Culp TD; DePhillips PA; Fu TM; Ha S
    J Biol Chem; 2015 Jun; 290(26):15985-95. PubMed ID: 25947373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.
    Lehmann C; Falk JJ; Büscher N; Penner I; Zimmermann C; Gogesch P; Sinzger C; Plachter B
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
    Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
    Loomis RJ; Lilja AE; Monroe J; Balabanis KA; Brito LA; Palladino G; Franti M; Mandl CW; Barnett SW; Mason PW
    Vaccine; 2013 Jan; 31(6):919-26. PubMed ID: 23246547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
    Gerna G; Lilleri D
    New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
    J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.
    Becke S; Aue S; Thomas D; Schader S; Podlech J; Bopp T; Sedmak T; Wolfrum U; Plachter B; Reyda S
    Vaccine; 2010 Aug; 28(38):6191-8. PubMed ID: 20655401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection.
    Lilleri D; Kabanova A; Revello MG; Percivalle E; Sarasini A; Genini E; Sallusto F; Lanzavecchia A; Corti D; Gerna G
    PLoS One; 2013; 8(3):e59863. PubMed ID: 23555812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.